Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People

Set Alert for People

Cipla's COO Steps Down

Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.

Leadership Strategy

Neuraxpharm Expands Into Portugal

Neuraxpharm is aiming to expand in the Portuguese market with its first commercial launch lined up for December. Javier Mercadé will be heading up the southern European region comprising Italy, Spain and now Portugal.

Strategy Appointments

Endo Starts Search For Campanelli’s Successor

With Endo’s CEO Paul Campanelli intending to step down for personal reasons, the US brands and generics player’s board has started to look for external and internal candidates to take over.

Leadership Appointments

Who’s Hired? Biocon Appoints A New CEO

Biocon has appointed a new CEO, while Mundipharma and Acino have named regional managers. At the same time, Nelipak has also appointed a new CEO.

Appointments Strategy

Who's Hired? Teva And Lupin Shake Up Supply Chain

Teva has announced a leadership change in its global operations, while Lupin has made a key appointment to focus on quality and compliance. Among other changes in leadership roles, Olainfarm has seen one of its six management board members resign. 

Appointments Strategy

People Round-Up: Alvotech Appoints Science Chief As Read Exits Pfizer

Alvotech has brought in a Pfizer biosimilars specialist as chief scientific officer, while Lupin has recruited a women’s health expert to head its US Specialty business. And Ian Read is to retire as Pfizer’s chairman at the start of next year.  

Appointments Leadership
See All
UsernamePublicRestriction

Register